Sign in
Active, not recruitingNo phase

Incidence of Graves' Disease After COVID-19 Vaccination

Key facts

Who runs it
Laura ICONARU
Where
Belgium3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
161 people enrolled
Started
8 Nov 2022
Ended
31 Dec 2025
Type of study
Observational
Treatments tested
  • Data extraction
Record updated
8 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • All patients who developed 'de novo' Graves' disease between March 2020 (the beginning of the COVID-19 epidemic in Belgium) and October 2022

Who cannot take part

  • Use of thyroid-interfering drugs, such as lithium, amiodarone or immune checkpoint inhibitor therapy
  • Pre-existing Graves' disease (before March 2020)
  • Diagnosis of other thyroid disease, such as subacute or painless destructive thyroiditis
  • Pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

It is well known that an infection can be a triggering factor for the development of autoimmune thyroid disease. The COVID-19 pandemic was an example of this, with several reports of both subacute thyroiditis as well as Graves' disease occurring after experiencing SARS-CoV-2 disease. There have also been cases of Graves' disease reported after COVID-19 vaccination administration (<4 weeks between the vaccine and the development of hyperthyroidism). However, the current evidence is of low quality and consists mainly of case reports. A search strategy on October 3, 2022, in the medical database PubMed could only retain one retrospective study on this subject. In this study by di Filippo et al., approximately 64 new cases of Graves' disease with hyperthyroidism were identified in the Milan region, Italy, in the year 2021, of which 20 patients had an onset within 4 weeks following COVID vaccine administration (31.2%).

Read full original descriptionShow less

The investigators would like to increase the knowledge about the possible link between COVID-19 (both the disease and the vaccination) and Graves' disease, by means of a case-control analysis of all 'de novo' cases of Graves' hyperthyroidism described in the C.H.U. Brugmann. The investigators want to investigate whether Graves' disease after vaccination would be clinically different from the "classic" Graves' disease, thereby describing factors such as the duration of the disease, the level of thyroid-stimulating immunoglobulins (TSI), the percentage of T3-dominant Graves' disease, or the dose of thyreostatics (such as strumazole) required to control the disease.

The group in the trial

  • 'de novo' Graves' disease

    All patients who developed 'de novo' Graves' disease between March 2020 (the beginning of the COVID-19 epidemic in Belgium) and October 2022

    Treatment: Data extraction

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Incidence of Graves' Disease After COVID-19 Vaccination: a Retrospective Analysis
Record updated
8 October 2025